Incannex Healthcare Gestion

Gestion contrôle des critères 2/4

Le PDG Incannex Healthcare est Joel Latham, nommé en Jun2018, a un mandat de 5.5 ans. La rémunération annuelle totale est A$ 3.03M, composée du salaire de 27% et des bonus 73%, y compris les actions et options de la société. détient directement 0.06% des actions de la société, d'une valeur de A$ 59.16K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.4 ans et 4.3 ans.

Informations clés

Joel Latham

Directeur général

AU$3.0m

Rémunération totale

Pourcentage du salaire du PDG	27.0%
Durée du mandat du directeur général	5.5yrs
Propriété du PDG	0.06%
Durée moyenne d'occupation des postes de direction	2.4yrs
Durée moyenne du mandat des membres du conseil d'administration	4.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Joel Latham a-t-elle évolué par rapport aux bénéfices de Incannex Healthcare?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2023	AU$3m	AU$820k	-AU$20m
Mar 31 2023	n/a	n/a	-AU$19m
Dec 31 2022	n/a	n/a	-AU$18m
Sep 30 2022	n/a	n/a	-AU$17m
Jun 30 2022	AU$2m	AU$534k	-AU$15m
Mar 31 2022	n/a	n/a	-AU$14m
Dec 31 2021	n/a	n/a	-AU$13m
Sep 30 2021	n/a	n/a	-AU$12m
Jun 30 2021	AU$636k	AU$279k	-AU$11m
Dec 31 2020	n/a	n/a	-AU$6m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$390k	AU$227k	-AU$4m
Dec 31 2019	n/a	n/a	-AU$2m
Sep 30 2019	n/a	n/a	-AU$2m
Jun 30 2019	AU$204k	AU$170k	-AU$1m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	n/a	n/a	-AU$3m
Sep 30 2018	n/a	n/a	-AU$3m
Jun 30 2018	AU$162k	AU$121k	-AU$3m

Rémunération vs marché: La rémunération totale de Joel ($USD 2.00M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 299.41K ).

Rémunération et revenus: La rémunération de Joel a augmenté alors que l'entreprise n'est pas rentable.

PDG

Joel Latham (33 yo)

5.5yrs

Titularisation

AU$3,033,966

Compensation

Mr. Joel Bradley Latham has been Chief Executive Officer at Incannex Healthcare Limited (also known as Impression Healthcare Ltd.) since June 29, 2018, Managing Director and Executive Director since July 2...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Joel Latham	MD, CEO & Executive Director	5.5yrs	AU$3.03m	0.060% A$ 59.2k
Madhukar Bhalla	CFO & Company Secretary	2.4yrs	AU$84.00k	pas de données
Lekhram Changoer	Chief Technical Officer	1.5yrs	AU$157.50k	pas de données
Mark Bleackley	Chief Scientific Officer	no data	pas de données	pas de données
John Michailidis	Chief Executive Officer of IncannexTM	4.1yrs	pas de données	pas de données
Rosemarie Walsh	VP of Clinical Operations & Member of the Advisory Board	no data	pas de données	pas de données
Joseph Swan	Head of Finance	1.3yrs	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Gestion expérimentée: L'équipe de direction de IHL est considérée comme expérimentée (ancienneté moyenne 2.4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Joel Latham	MD, CEO & Executive Director	4.4yrs	AU$3.03m	0.060% A$ 59.2k
Mark Bleackley	Chief Scientific Officer	no data	pas de données	pas de données
Rosemarie Walsh	VP of Clinical Operations & Member of the Advisory Board	no data	pas de données	pas de données
Terrance O'Brien	Member of the Advisory Board	no data	pas de données	pas de données
George Anastassov	Non-Executive Director	1.5yrs	AU$175.87k	0.17% A$ 166.8k
Troy Valentine	Independent Non-Executive Chairman	6yrs	AU$1.38m	0.031% A$ 30.8k
Peter Widdows	Independent Non-Executive Director	5.8yrs	AU$316.23k	0.043% A$ 42.6k
Rondhir Jithoo	Member of Medical Advisory Board	4.3yrs	pas de données	pas de données
Paul Liknaitzky	Member of Medical Advisory Board	3.3yrs	pas de données	pas de données
Jennifer Walsh	Member of the Advisory Board	no data	pas de données	pas de données
Robert Clark	Non-Executive Director	1.3yrs	AU$176.09k	0% A$ 0

4.3yrs

Durée moyenne de l'emploi

52.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de IHL sont considérés comme expérimentés (ancienneté moyenne 4.3 ans).

Incannex Healthcare Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Incannex Healthcare Inc. Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Less than half of directors are independent

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Less than half of directors are independent

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited Announces Board Changes

Recent updates

Incannex Healthcare Inc. Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Incannex Healthcare Inc. Receives Approval from the US Food and Drug Administration to Conduct its Investigational New Drug Opening Phase 2 Clinical Trial

Incannex Healthcare Inc. Completes Patient Dosing in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate IHL-42X

Incannex Healthcare Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder

Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder

Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia

Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity

Incannex Healthcare Limited Files Form 15

New minor risk - Share price stability

New minor risk - Financial data availability

Psychennex Pty Ltd Commences Preparations of an Investigational New Drug Application to the U.S. Food and Drug Administration

Incannex Healthcare Limited Receives Approval from the US Food and Drug Administration to Conduct Its Investigational New Drug Opening Pivotal IHL-42X Phase 2/3 Clinical Trial in the United States

New minor risk - Market cap size

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited Receives HREC Approval Ph 2 Clinical Trial for IHL675

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’S Proprietary Drug for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

Incannex Healthcare Limited Announces Independent Data Review Commences for PH 2 Trial Psilocybin

Incannex Healthcare Limited Expands Intellectual Property Position over IHL-42X

Incannex Healthcare Limited Announces Development Update for IHL-42X for Obstructive Sleep Apnoea

Less than half of directors are independent

Incannex Healthcare Limited Announces Positive Preliminary Data from Ihl-675A Ph 1 Trial

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.012 loss in FY 2021)

Less than half of directors are independent

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders.

Incannex Healthcare Limited Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Incannex Healthcare Limited Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Incannex Healthcare Limited Announces Board Changes

Less than half of directors are independent

Incannex Healthcare Limited Approves Election of George Anastassov as Director

Incannex Healthcare Limited Announces Positive Results from Phase 2 Clinical Trial Investigating the Effect of IHL-42X for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Announces Positive Pre-IND Meeting with FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders for $93.3 million on May 12, 2022.

Incannex Healthcare Limited Announces IHL-216A Was Observed to Have A Strong Neuroprotective Effect in A Widely Known Model of Sports Concussion

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Incannex Healthcare Limited Completes Dosing Patients in Phase 2 Proof-Of-Concept Trial of IHL-42X for the Treatment of Obstructive Sleep Apnoea

First half 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2020)

Incannex Healthcare Limited Files International Patent Application Entitled "Methods for the Treatment of Obstructive Sleep Apnoea" as Part of the IHL-42X Development Program

Company Secretary Glenn Fowles has left the company

Incannex Healthcare Limited Initiates Sixth Research Program Following More Positive in Vivo Results

Incannex Healthcare Limited Partners with Monash Trauma Group At the Department of Neuroscience to Conduct Study in Relation to Neuroprotective Capability of IHL-216A

Incannex Healthcare Limited Initiates Fifth Research Program Following Further Positive in Vivo Results

New 90-day high: AU$0.23

Incannex Healthcare Limited Receives Positive Results from Another in Vivo (Animal) Study

Incannex Healthcare Limited, Annual General Meeting, Jan 25, 2021

Incannex Healthcare Limited Announces Positive Results from IH-216A TBI/Concussion Study

Incannex Healthcare Limited Receives Positive Results from Eurofins

Incannex Healthcare Limited Receives Further Positive Results from Eurofins (Taiwan)

Incannex Healthcare Limited Receives Ethics Approval for Phase 2 OSA Trial

Incannex Healthcare Limited Appoints Paul Liknaitzky to Medical Advisory Board as Scientific Officer

Full year earnings released - AU$0.0058 loss per share

An unknown buyer acquired Gameday International Pty Ltd from Incannex Healthcare Limited (ASX:IHL) for $0.29 million.

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen